Mental Health Center Sofia EOOD — Clinical Trial Site

14 Registered trials

7 Currently recruiting

Organisation

Mental Health Center Sofia EOOD

Location

Sofia, Bulgaria

Identifier

ORG-100046427

Address

Bulevard Slivnitsa 309, 1202, Bulgaria

Departments

A day hospital Unit
Consultative-Diagnostic Block
Department for active treatment of individuals with severe psychiatric disorders – Psychiatry, Level
Department of active treatment of persons with severe mental disorders - Psychiatry
N/A
NA

Clinical trials at this site (14)

Search interface

Open-label Extension of KarXT + KarX-EC for Agitation in Alzheimer’s Disease Recruiting

2024-519994-20-00 Agitation Associated with Alzheimer’s Disease 5 2026-06-01
A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Monotherapy Study of the Efficacy, Safety, and Tolerability of SPT-300 in Ad… Recruiting

2025-521240-37-00 Major Depressive Disorder (MDD), with or without Anxiou 4 2025-09-11
DT-101 in Adults with Major Depressive Disorder Recruiting

2025-522784-15-00 Major Depressive Disorder 4 2026-03-24
A 6-Week, Multicenter, Open-Label, Monotherapy, Extension Study of SPT-300 in Adults with Major Depressive Disorder, With or Without Anxious… Recruiting

2025-522347-18-00 Major Depressive Disorder (MDD), with or without Anxiou 4 2025-11-26
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease. Recruiting

2025-520613-31-00 Agitation Associated with Alzheimer’s Disease 5 2025-10-31
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder Recruiting

2024-520333-68-00 Major Depressive Disorder 5 2025-09-26
A study to assess the efficacy and safety of lumateperone in patients with major depressive disorder Recruiting

2023-503836-41-00 Major Depressive Disorder 5 2025-03-10
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as … Ended

2024-511557-21-00 Major Depressive Disorder (MDD) with Moderate-to-severe 5 2024-11-14
A Clinical Study that will measure how well SEP-363856 works and how safe it is in adults with Generalized Anxiety Disorder Ended

2022-502077-42-00 generalised anxiety disorder 10 2023-09-14
A study to evaluate if aticaprant added to a current antidepressant and given up to one year is safe and would help improve depression. Ended

2023-508163-74-00 Major Depressive Disorder 5 2023-06-12
A rollover study for subjects that complete KAR-012 trial, to assess Long-term Safety and Tolerability of Adjunctive KarXT in Subjects with … Ended

2024-510773-20-00 Schizophrenia 5 2023-06-12
A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (ARISE) Ended

2024-510770-25-00 Schizophrenia 5 2023-03-22
A 52-week, Open-label Trial of CVL-231 in Adult Participants With Schizophrenia Ended

2024-511441-19-00 Schizophrenia 4 2023-03-08
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects with Schizophrenia Ended

2023-508433-14-00 Schizophrenia 5 2022-09-30